We confirmed that CYLD biallelic loss was independent for each sample, reinforcing that each tumor arose independently: loss of the wild-type allele was observed either by LOH affecting 16q (31/42 tumors) or by a second mutation in CYLD (9/42), consistent with the loss of CYLD occurring across all benign and some malignant tumors in CCS. The gene discussed is CYLD; the disease is neoplasm.